bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.5120
0.00 (0.00%)
Apr 25, 2025, 7:00 AM EDT - Market open
bioAffinity Technologies Revenue
In the year 2024, bioAffinity Technologies had annual revenue of $9.36M with 269.68% growth. bioAffinity Technologies had revenue of $2.21M in the quarter ending December 31, 2024, a decrease of -0.26%.
Revenue (ttm)
$9.36M
Revenue Growth
+269.68%
P/S Ratio
0.66
Revenue / Employee
$164,246
Employees
57
Market Cap
9.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
Dec 31, 2022 | 4.80K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BIAF News
- 8 days ago - bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost - Business Wire
- 25 days ago - bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - Business Wire
- 4 weeks ago - Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer - Business Wire
- 5 weeks ago - Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence - Business Wire
- 6 weeks ago - Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer - Business Wire
- 7 weeks ago - bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth - Business Wire
- 2 months ago - WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million - PRNewsWire
- 2 months ago - bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million - Business Wire